Therapeutic Vaccine Designed To Reduce Recurrence Of Cervical Cancer Under Study | Latest News RSS feed

Therapeutic Vaccine Designed To Reduce Recurrence Of Cervical Cancer Under Study - Latest News


Therapeutic vaccine designed to reduce recurrence of cervical cancer under study

Dr. Sharad A. Ghamande, chief of the Section of Gynecologic Oncology at the Medical College of Georgia and associate director for clinical research at the Georgia Cancer Center at Augusta University. ... read more

Advaxis: First Cancer Vaccine For Cervical Cancer To Be In Pivotal Trial

Advaxis (NASDAQ:ADXS) is a development stage biotechnology company focused on the research, development and commercialization of safe and effective therapeutic cancer vaccines ... recurrent cervical c... read more

The Latest Cancer Research News to Cheer About

Now a trial is studying whether women with ER-positive cancer can safely stop anti-estrogen therapy ... a potential vaccine that would use a woman’s immune system to prevent a recurrence of ovarian ca... read more

Looking for another news?


Inovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater China

VGX-3100 is the world’s first therapeutic vaccine being developed for ... that targets the underlying cause of cervical dysplasia, providing an opportunity for women to reduce their risk of cervical c... read more


NeuVax breast cancer vaccine tested at Memorial Regional Cancer Center

We have vaccines to prevent mumps, measles, polio, and even cervical cancer ... kind of study." Jennifer decided to take part, and during the first part of the trial, she got three shots of Herceptin ... read more

Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer

The innovaTV 204 trial is intended to support potential registration under the U.S ... “In a prior study, tisotumab vedotin demonstrated encouraging results in previously treated recurrent and/or meta... read more

Advaxis Vs. Inovio: A Head To Head Comparison Of 2 Cervical Cancer Vaccines

Of the plethora of therapies under development, vaccines ... for cervical cancer patients. Finally, Advaxis is expected to release mid-dosing results from its U.S. Phase 2 clinical trial by the end of ... read more

UPenn Doses First Two Dogs in ADXS-HER2 Canine Osteosarcoma Study

In April 2012, Advaxis’ lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine ... study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US stud... read more

FDA approves Merck's Zinplava to reduce recurrence of Clostridium difficile infection

International pharmaceutical company Merck has announced that the U.S. Food and Drug Administration (FDA) has approved Zinplava (its brand name for bezlotoxumab) to reduce recurrence ... vaccines, mon... read more

Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer

Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (SGEN) announced today a decision to start a Phase II study of tisotumab vedotin in patients with recurrent ... (HPV) vaccine have had a ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us